Identification and characterisation of pathogenic and non-pathogenic FGF14 repeat expansions.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
03 Sep 2024
Historique:
received: 08 02 2024
accepted: 27 08 2024
medline: 4 9 2024
pubmed: 4 9 2024
entrez: 3 9 2024
Statut: epublish

Résumé

Repeat expansions in FGF14 cause autosomal dominant late-onset cerebellar ataxia (SCA27B) with estimated pathogenic thresholds of 250 (incomplete penetrance) and 300 AAG repeats (full penetrance), but the sequence of pathogenic and non-pathogenic expansions remains unexplored. Here, we demonstrate that STRling and ExpansionHunter accurately detect FGF14 expansions from short-read genome data using outlier approaches. By combining long-range PCR and nanopore sequencing in 169 patients with cerebellar ataxia and 802 controls, we compare FGF14 expansion alleles, including interruptions and flanking regions. Uninterrupted AAG expansions are significantly enriched in patients with ataxia from a lower threshold (180-200 repeats) than previously reported based on expansion size alone. Conversely, AAGGAG hexameric expansions are equally frequent in patients and controls. Distinct 5' flanking regions, interruptions and pre-repeat sequences correlate with repeat size. Furthermore, pure AAG (pathogenic) and AAGGAG (non-pathogenic) repeats form different secondary structures. Regardless of expansion size, SCA27B is a recognizable clinical entity characterized by frequent episodic ataxia and downbeat nystagmus, similar to the presentation observed in a family with a previously unreported nonsense variant (SCA27A). Overall, this study suggests that SCA27B is a major overlooked cause of adult-onset ataxia, accounting for 23-31% of unsolved patients. We strongly recommend re-evaluating pathogenic thresholds and integrating expansion sequencing into the molecular diagnostic process.

Identifiants

pubmed: 39227614
doi: 10.1038/s41467-024-52148-1
pii: 10.1038/s41467-024-52148-1
doi:

Substances chimiques

fibroblast growth factor 14 0
Fibroblast Growth Factors 62031-54-3

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7665

Informations de copyright

© 2024. The Author(s).

Références

Coarelli, G., Coutelier, M. & Durr, A. Autosomal dominant cerebellar ataxias: new genes and progress towards treatments. Lancet Neurol. 22, 735–749 (2023).
pubmed: 37479376 doi: 10.1016/S1474-4422(23)00068-6
Ashizawa, T., Oz, G. & Paulson, H. L. Spinocerebellar ataxias: prospects and challenges for therapy development. Nat. Rev. Neurol. 14, 590–605 (2018).
pubmed: 30131520 pmcid: 6469934 doi: 10.1038/s41582-018-0051-6
van Swieten, J. C. et al. A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebellar ataxia. Am. J. Hum. Genet 72, 191–199 (2003).
pubmed: 12489043 doi: 10.1086/345488
Choquet, K., La Piana, R. & Brais, B. A novel frameshift mutation in FGF14 causes an autosomal dominant episodic ataxia. Neurogenetics 16, 233–236 (2015).
pubmed: 25566820 doi: 10.1007/s10048-014-0436-7
Dalski, A. et al. Mutation analysis in the fibroblast growth factor 14 gene: frameshift mutation and polymorphisms in patients with inherited ataxias. Eur. J. Hum. Genet 13, 118–120 (2005).
pubmed: 15470364 doi: 10.1038/sj.ejhg.5201286
Pellerin, D. et al. Deep intronic FGF14 GAA repeat expansion in late-onset cerebellar ataxia. N. Engl. J. Med. 388, 128–141 (2023).
pubmed: 36516086 doi: 10.1056/NEJMoa2207406
Rafehi, H. et al. An intronic GAA repeat expansion in FGF14 causes the autosomal-dominant adult-onset ataxia SCA50/ATX-FGF14. Am. J. Hum. Genet 110, 105–119 (2023).
pubmed: 36493768 doi: 10.1016/j.ajhg.2022.11.015
Rafehi, H. et al. An intronic GAA repeat expansion in FGF14 causes the autosomal-dominant adult-onset ataxia SCA27B/ATX-FGF14. Am. J. Hum. Genet 110, 1018 (2023).
pubmed: 37267898 pmcid: 10257192 doi: 10.1016/j.ajhg.2023.05.005
Laezza, F. et al. FGF14 N-terminal splice variants differentially modulate Nav1.2 and Nav1.6-encoded sodium channels. Mol. Cell Neurosci. 42, 90–101 (2009).
pubmed: 19465131 pmcid: 2832592 doi: 10.1016/j.mcn.2009.05.007
Xiao, M., Bosch, M. K., Nerbonne, J. M. & Ornitz, D. M. FGF14 localization and organization of the axon initial segment. Mol. Cell Neurosci. 56, 393–403 (2013).
pubmed: 23891806 doi: 10.1016/j.mcn.2013.07.008
Pablo, J. L. & Pitt, G. S. FGF14 is a regulator of KCNQ2/3 channels. Proc. Natl Acad. Sci. USA 114, 154–159 (2017).
pubmed: 27994149 doi: 10.1073/pnas.1610158114
Pellerin, D. et al. Non-GAA repeat expansions in FGF14 are likely not pathogenic-reply to: “shaking up ataxia: FGF14 and RFC1 repeat expansions in affected and unaffected members of a Chilean family. Mov. Disord. 38, 1575–1577 (2023).
pubmed: 37565404 doi: 10.1002/mds.29552
Saffie Awad, P. et al. Shaking up ataxia: FGF14 and RFC1 repeat expansions in affected and unaffected members of a Chilean family. Mov. Disord. 38, 1107–1109 (2023).
pubmed: 37246629 doi: 10.1002/mds.29390
Wenning, G. K. et al. The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov. Disord. 37, 1131–1148 (2022).
pubmed: 35445419 pmcid: 9321158 doi: 10.1002/mds.29005
Ando, M. et al. Clinical variability associated with intronic FGF14 GAA repeat expansion in Japan. Ann. Clin. Transl. Neurol. 11, 96–104 (2024).
pubmed: 37916889 doi: 10.1002/acn3.51936
Wilke, C. et al. GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response. Brain 146, 4144–4157 (2023).
pubmed: 37165652 doi: 10.1093/brain/awad157
Wirth, T. et al. Natural history and phenotypic spectrum of GAA-FGF14 sporadic late-onset cerebellar ataxia (SCA27B). Mov. Disord. 38, 1950–1956 (2023).
pubmed: 37470282 doi: 10.1002/mds.29560
Miura, S. et al. Spinocerebellar ataxia 27 with a novel nonsense variant (Lys177X) in FGF14. Eur. J. Med. Genet 62, 172–176 (2019).
pubmed: 30017992 doi: 10.1016/j.ejmg.2018.07.005
Humbertclaude, V. et al. Benign paroxysmal torticollis, benign paroxysmal vertigo, and benign tonic upward gaze are not benign disorders. Dev. Med Child Neurol. 60, 1256–1263 (2018).
pubmed: 29926469 doi: 10.1111/dmcn.13935
Brusse, E. et al. Spinocerebellar ataxia associated with a mutation in the fibroblast growth factor 14 gene (SCA27): A new phenotype. Mov. Disord. 21, 396–401 (2006).
pubmed: 16211615 doi: 10.1002/mds.20708
Hengel, H. et al. As frequent as polyglutamine spinocerebellar ataxias: SCA27B in a large german autosomal dominant ataxia cohort. Mov. Disord. 38, 1557–1558 (2023).
pubmed: 37528564 doi: 10.1002/mds.29559
Kypr, J., Kejnovska, I., Renciuk, D. & Vorlickova, M. Circular dichroism and conformational polymorphism of DNA. Nucleic Acids Res 37, 1713–1725 (2009).
pubmed: 19190094 pmcid: 2665218 doi: 10.1093/nar/gkp026
Vorlickova, M., Kejnovska, I., Bednarova, K., Renciuk, D. & Kypr, J. Circular dichroism spectroscopy of DNA: from duplexes to quadruplexes. Chirality 24, 691–698 (2012).
pubmed: 22696273 doi: 10.1002/chir.22064
Vorlickova, M. et al. Circular dichroism and guanine quadruplexes. Methods 57, 64–75 (2012).
pubmed: 22450044 doi: 10.1016/j.ymeth.2012.03.011
Del Villar-Guerra, R., Trent, J. O. & Chaires, J. B. G-quadruplex secondary structure obtained from circular dichroism spectroscopy. Angew. Chem. Int Ed. Engl. 57, 7171–7175 (2018).
pubmed: 29076232 pmcid: 5920796 doi: 10.1002/anie.201709184
Chauca-Diaz, A. M., Choi, Y. J. & Resendiz, M. J. Biophysical properties and thermal stability of oligonucleotides of RNA containing 7,8-dihydro-8-hydroxyadenosine. Biopolymers 103, 167–174 (2015).
pubmed: 25363418 doi: 10.1002/bip.22579
Bhattacharyya, D., Mirihana Arachchilage, G. & Basu, S. Metal cations in G-quadruplex folding and stability. Front Chem. 4, 38 (2016).
pubmed: 27668212 pmcid: 5016522 doi: 10.3389/fchem.2016.00038
Zaccaria, F. & Fonseca Guerra, C. RNA versus DNA G-Quadruplex: the origin of increased stability. Chemistry 24, 16315–16322 (2018).
pubmed: 30215872 pmcid: 6282516 doi: 10.1002/chem.201803530
Garg, A. & Heinemann, U. A novel form of RNA double helix based on G.U and C.A(+) wobble base pairing. RNA 24, 209–218 (2018).
pubmed: 29122970 pmcid: 5769748 doi: 10.1261/rna.064048.117
Dashnow, H. et al. STRling: a k-mer counting approach that detects short tandem repeat expansions at known and novel loci. Genome Biol. 23, 257 (2022).
pubmed: 36517892 pmcid: 9753380 doi: 10.1186/s13059-022-02826-4
Dolzhenko, E. et al. Detection of long repeat expansions from PCR-free whole-genome sequence data. Genome Res. 27, 1895–1903 (2017).
pubmed: 28887402 pmcid: 5668946 doi: 10.1101/gr.225672.117
Halman, A., Dolzhenko, E. & Oshlack, A. STRipy: A graphical application for enhanced genotyping of pathogenic short tandem repeats in sequencing data. Hum. Mutat. 43, 859–868 (2022).
pubmed: 35395114 pmcid: 9541159 doi: 10.1002/humu.24382
Pellerin, D. et al. Intronic FGF14 GAA repeat expansions are a common cause of ataxia syndromes with neuropathy and bilateral vestibulopathy. J. Neurol. Neurosurg. Psychiatry 95, 175–179 (2024).
pubmed: 37399286 doi: 10.1136/jnnp-2023-331490
Novis, L. E. et al. Frequency of GAA-FGF14 ataxia in a large cohort of brazilian patients with unsolved adult-onset cerebellar ataxia. Neurol. Genet 9, e200094 (2023).
pubmed: 37646005 pmcid: 10461713 doi: 10.1212/NXG.0000000000200094
Iruzubieta, P. et al. Frequency and phenotypic spectrum of spinocerebellar ataxia 27B and other genetic ataxias in a Spanish cohort of late-onset cerebellar ataxia. Eur. J. Neurol. 30, 3828–3833 (2023).
pubmed: 37578187 doi: 10.1111/ene.16039
Bonnet, C. et al. Optimized testing strategy for the diagnosis of GAA-FGF14 ataxia/spinocerebellar ataxia 27B. Sci. Rep. 13, 9737 (2023).
pubmed: 37322040 pmcid: 10272173 doi: 10.1038/s41598-023-36654-8
Ashton, C. et al. Spinocerebellar ataxia 27B: episodic symptoms and acetazolamide response in 34 patients. Brain Commun. 5, fcad239 (2023).
pubmed: 37705681 pmcid: 10495284 doi: 10.1093/braincomms/fcad239
Pellerin, D. et al. GAA-FGF14 disease: defining its frequency, molecular basis, and 4-aminopyridine response in a large downbeat nystagmus cohort. EBioMedicine 102, 105076 (2024).
pubmed: 38507876 pmcid: 10960126 doi: 10.1016/j.ebiom.2024.105076
Foucard, C. et al. Paroxysmal ataxia: a characteristic feature of FGF14 repeat expansion (SCA27B). Neurol. Genet 10, e200118 (2024).
pubmed: 38170134 doi: 10.1212/NXG.0000000000200118
Mereaux, J. L. et al. Clinical and genetic keys to cerebellar ataxia due to FGF14 GAA expansions. EBioMedicine 99, 104931 (2024).
pubmed: 38150853 doi: 10.1016/j.ebiom.2023.104931
Barbier, M. et al. Intermediate repeat expansions of TBP and STUB1: genetic modifier or pure digenic inheritance in spinocerebellar ataxias? Genet Med. 25, 100327 (2023).
pubmed: 36422518 doi: 10.1016/j.gim.2022.10.009
Magri, S. et al. Digenic inheritance of STUB1 variants and TBP polyglutamine expansions explains the incomplete penetrance of SCA17 and SCA48. Genet Med. 24, 29–40 (2022).
pubmed: 34906452 doi: 10.1016/j.gim.2021.08.003
Rajagopal, S., Donaldson, J., Flower, M., Hensman Moss, D. J. & Tabrizi, S. J. Genetic modifiers of repeat expansion disorders. Emerg. Top. Life Sci. 7, 325–337 (2023).
pubmed: 37861103 pmcid: 10754329 doi: 10.1042/ETLS20230015
Laezza, F. et al. The FGF14(F145S) mutation disrupts the interaction of FGF14 with voltage-gated Na+ channels and impairs neuronal excitability. J. Neurosci. 27, 12033–12044 (2007).
pubmed: 17978045 pmcid: 6673376 doi: 10.1523/JNEUROSCI.2282-07.2007
Pellerin, D. et al. A common flanking variant is associated with enhanced stability of the FGF14-SCA27B repeat locus. Nat. Genet 56, 1366–1370 (2024).
pubmed: 38937606 doi: 10.1038/s41588-024-01808-5
Abdi, M. H., Zamiri, B., Pazuki, G., Sardari, S. & Pearson, C. E. Pathogenic CANVAS-causing but not nonpathogenic RFC1 DNA/RNA repeat motifs form quadruplex or triplex structures. J. Biol. Chem. 299, 105202 (2023).
pubmed: 37660923 pmcid: 10563062 doi: 10.1016/j.jbc.2023.105202
Groh, M., Lufino, M. M., Wade-Martins, R. & Gromak, N. R-loops associated with triplet repeat expansions promote gene silencing in Friedreich ataxia and fragile X syndrome. PLoS Genet 10, e1004318 (2014).
pubmed: 24787137 pmcid: 4006715 doi: 10.1371/journal.pgen.1004318
Butler, J. S. & Napierala, M. Friedreich’s ataxia–a case of aberrant transcription termination? Transcription 6, 33–36 (2015).
pubmed: 25831023 pmcid: 4581357 doi: 10.1080/21541264.2015.1026538
Zhang, J., Fakharzadeh, A., Pan, F., Roland, C. & Sagui, C. Atypical structures of GAA/TTC trinucleotide repeats underlying Friedreich’s ataxia: DNA triplexes and RNA/DNA hybrids. Nucleic Acids Res. 48, 9899–9917 (2020).
pubmed: 32821947 pmcid: 7515735 doi: 10.1093/nar/gkaa665
Schmermund, A. et al. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. Am. Heart J. 144, 212–218 (2002).
pubmed: 12177636 doi: 10.1067/mhj.2002.123579
Jacobi, H. et al. Inventory of Non-Ataxia Signs (INAS): validation of a new clinical assessment instrument. Cerebellum 12, 418–428 (2013).
pubmed: 23090211 doi: 10.1007/s12311-012-0421-3
Schmitz-Hubsch, T. et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66, 1717–1720 (2006).
pubmed: 16769946 doi: 10.1212/01.wnl.0000219042.60538.92
Trouillas, P. et al. International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome. the ataxia neuropharmacology committee of the world federation of neurology. J. Neurol. Sci. 145, 205–211 (1997).
pubmed: 9094050 doi: 10.1016/S0022-510X(96)00231-6
Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnetjournal 1, 10 (2011).
Li, H. et al. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv:1303.3997v2. https://doi.org/10.48550/arXiv.1303.3997 (2013).
Vasimuddin M., Misra, S., Li, H. & Aluru, S. Efficient architecture-aware acceleration of BWA-MEM for multicore systems. 2019 IEEE International Parallel and Distributed Processing Symposium (IPDPS), Rio de Janeiro, Brazil, 314–324, https://doi.org/10.1109/IPDPS.2019.00041 (2019).
Jung, Y. & Han, D. BWA-MEME: BWA-MEM emulated with a machine learning approach. Bioinformatics 38, 2404–2413 (2022).
pubmed: 35253835 doi: 10.1093/bioinformatics/btac137
Faust, G. G. & Hall, I. M. SAMBLASTER: fast duplicate marking and structural variant read extraction. Bioinformatics 30, 2503–2505 (2014).
pubmed: 24812344 pmcid: 4147885 doi: 10.1093/bioinformatics/btu314
Danecek, P. et al. Twelve years of SAMtools and BCFtools. Gigascience 10, giab008 (2021).
pubmed: 33590861 pmcid: 7931819 doi: 10.1093/gigascience/giab008
Dolzhenko, E. et al. ExpansionHunter Denovo: a computational method for locating known and novel repeat expansions in short-read sequencing data. Genome Biol. 21, 102 (2020).
pubmed: 32345345 pmcid: 7187524 doi: 10.1186/s13059-020-02017-z
Florian, R. T. et al. Unstable TTTTA/TTTCA expansions in MARCH6 are associated with familial adult myoclonic epilepsy type 3. Nat. Commun. 10, 4919 (2019).
pubmed: 31664039 pmcid: 6820781 doi: 10.1038/s41467-019-12763-9
Corbett, M. A. et al. Intronic ATTTC repeat expansions in STARD7 in familial adult myoclonic epilepsy linked to chromosome 2. Nat. Commun. 10, 4920 (2019).
pubmed: 31664034 pmcid: 6820779 doi: 10.1038/s41467-019-12671-y
Molder, F. et al. Sustainable data analysis with Snakemake. F1000Res 10, 33 (2021).
pubmed: 34035898 pmcid: 8114187 doi: 10.12688/f1000research.29032.2
Kilpert F. Identification and characterisation of pathogenic and non-pathogenic FGF14 repeat expansions. kilpert/FGF14_basecalling. https://doi.org/10.5281/zenodo.12655177 (2024).
Kilpert F. Identification and characterisation of pathogenic and non-pathogenic FGF14 repeat expansions. kilpert/FGF14_analyses. https://doi.org/10.5281/zenodo.12654084 (2024).
Oxford Nanopore Technologies. Guppy. https://community.nanoporetech.com/docs/prepare/library_prep_protocols/Guppyprotocol/v/gpb_2003_v1_revax_14dec2018/guppy-software-overview .
Leger, A. L. & Leonardi, T. pycoQC, interactive quality control for Oxford Nanopore Sequencing. J. Open Source Softw. 4, 1236 (2019).
doi: 10.21105/joss.01236
De Coster, W. & Rademakers, R. NanoPack2: population-scale evaluation of long-read sequencing data. Bioinformatics 39, btad311 (2023).
pubmed: 37171891 pmcid: 10196664 doi: 10.1093/bioinformatics/btad311
Bushnell B. BBMap: A Fast, Accurate, Splice-Aware Aligner. Lawrence Berkeley National Laboratory LBNL Report #: LBNL-7065E Retrieved from https://escholarship.org/content/qt1h3515gn/qt1h3515gn_noSplash_d7c10945f4edf149785bacad80ec9f9c.pdf (2014).

Auteurs

Lars Mohren (L)

Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Friedrich Erdlenbruch (F)

Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Elsa Leitão (E)

Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Fabian Kilpert (F)

Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

G Sebastian Hönes (GS)

Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Sabine Kaya (S)

Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Christopher Schröder (C)

Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Andreas Thieme (A)

Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Marc Sturm (M)

Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.

Joohyun Park (J)

Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.

Agatha Schlüter (A)

Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.

Montserrat Ruiz (M)

Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.

Moisés Morales de la Prida (M)

Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
Neuromuscular Unit, Neurology Department, Bellvitge University Hospital, Barcelona, Spain.

Carlos Casasnovas (C)

Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
Neuromuscular Unit, Neurology Department, Bellvitge University Hospital, Barcelona, Spain.

Kerstin Becker (K)

Cologne Center for Genomics (CCG), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.

Ulla Roggenbuck (U)

Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Sonali Pechlivanis (S)

Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Institute of Asthma and Allergy Prevention, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.

Frank J Kaiser (FJ)

Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Essener Zentrum für Seltene Erkrankungen (EZSE), Universitätsklinikum Essen, Essen, Germany.

Matthis Synofzik (M)

Division Translational Genomics of Neurodegenerative Diseases, Center for Neurology & Hertie Institute for Clinical Brain Research Tübingen, Tübingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

Thomas Wirth (T)

Service de Neurologie, Département de Neurologie, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, 1, Avenue Molière, Strasbourg, Cedex, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.
Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.

Mathieu Anheim (M)

Service de Neurologie, Département de Neurologie, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, 1, Avenue Molière, Strasbourg, Cedex, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.
Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.

Tobias B Haack (TB)

Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Centre for Rare Diseases, University of Tübingen, Tübingen, Germany.

Paul J Lockhart (PJ)

Bruce Lefroy Centre, Murdoch Children's Research Institute; Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia.

Karl-Heinz Jöckel (KH)

Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Aurora Pujol (A)

Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain.

Stephan Klebe (S)

Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Dagmar Timmann (D)

Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Christel Depienne (C)

Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany. christel.depienne@uk-essen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH